Skip to main content
Home
Latest news
Browse topics
Lupus Rheumatoid arthritis Spondyloarthropathies COVID-19 Browse all topics
In focus
Bimekizumab: Dual IL-17A/IL-17F inhibition in SpA Anifrolumab for the treatment of SLE JAK inhibitor safety: Weighing up the data and understanding the risks Rituximab and rheumatology practice in the COVID-19 era Safety snapshot: Upadacitinib in patients with PsA Repurposing rheumatology drugs for COVID-19 Telemedicine in rheumatology: COVID-19 and beyond Managing PsA in resource-limited settings
Conferences
ACR Convergence 2022 EULAR 2022 Congress
About us
Medicine Matters Rheumatology
EXTENDED SEARCH

14-06-2022 | EULAR 2022 | Conference coverage | Video

The BE MOBILE 1 and 2 trials of bimekizumab in axSpA

Désirée van der Heijde outlines the findings of two phase 3 trials demonstrating that bimekizumab may be beneficial for patients with nonradiographic axial spondyloarthritis or ankylosing spondylitis (2:54).

External Content

Click Play to display this content and agree to third party cookies. (>)

Update your current cookie settings.

Related content

25-05-2022 | Bimekizumab | Feature | Article

A quick guide to the phase 3 trials of bimekizumab in spondyloarthritis

14-06-2019 | Axial spondyloarthritis | EULAR 2019 | News

BE AGILE: Bimekizumab shows promise for ankylosing spondylitis

12-11-2019 | Ankylosing spondylitis | ACR/ARP 2019 | News

Bimekizumab benefits for ankylosing spondylitis extend beyond 12 weeks

04-06-2022 | EULAR 2022 | Conference coverage | News

Bimekizumab beneficial for psoriatic arthritis in phase 3 trials
Image Credits